Form 4: 10x Genomics Director Granted Significant Restricted Stock Units

John R. Stuelpnagel, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 Class A Common Stock Restricted Stock Units (RSUs) on June 3, 2025, increasing his direct beneficial ownership to 359,607 shares.

Summary

• Director John R. Stuelpnagel of 10x Genomics, Inc. (TXG) acquired 15,357 shares of Class A Common Stock.
• The acquisition occurred on June 3, 2025, and was a grant of Restricted Stock Units (RSUs) with a transaction price of $0.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs will vest in quarterly installments, with 1/4th vesting on each quarterly anniversary starting from May 21, 2025, contingent on continued service.
• Following this transaction, Mr. Stuelpnagel's direct beneficial ownership of Class A Common Stock is 359,607 shares.

Sentiment

Score: 7

Explanation: Positive, as it indicates continued alignment of a director's interests with shareholders through equity compensation, though it's a routine insider filing.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the director's interests with long-term shareholder value.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Negatives

• The transaction was a grant of RSUs, not an open market purchase, meaning there was no direct cash investment by the director.

Future Outlook

The granted Restricted Stock Units (RSUs) are scheduled to vest quarterly starting May 21, 2025, contingent on the director's continued service, indicating a long-term retention strategy and alignment of interests.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a common and standard form of equity compensation within the life sciences and technology industries, used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company.

Related Party Transactions

• The grant of Restricted Stock Units (RSUs) to Director John R. Stuelpnagel represents a standard equity compensation arrangement between the company and a related party (director).

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's long-term interests with those of the shareholders, potentially fostering better governance and strategic decisions.

Next Steps

• Continued vesting of the granted Restricted Stock Units (RSUs) on a quarterly basis, subject to the director's ongoing service.

Key Dates

Keywords

10x Genomics, TXG, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership